Cikloastragenol

Cikloastragenol je sapogenin koji je prisutan u biljci Astragalus membranaceus.[3] On je u prodaji pod imenima TA-65 ili TA-65MD u SAD-u. Proizvodi ga kompanija Telomerase Activation Sciences, Inc.. TA-65 se pojavio na tržištu 2005.

Cikloastragenol
Drugi nazivi Ciklogalegigenin, Astramembrangenin, TA-65
Identifikacija
CAS registarski broj 4605-18-5 DaY
PubChem[1][2] 44144539
Jmol-3D slike Slika 1
Svojstva
Molekulska formula C30H50O5
Molarna masa 490,72 g/mol

 DaY (šta je ovo?)   (verifikuj)

Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala

Infobox references

Cikloastragenol umereno povećava aktivnost telomeraze i proliferativni kapacitet CD4 i CD8 T ćelija.[4] Postoje indikacije da je on posebno efektivan kod citomegalovirus-pozitivnih osoba.[5]

Reference uredi

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Fauce, SR; Jamieson, BD; Chin, AC; Mitsuyasu, RT; Parish, ST; Ng, HL; Kitchen, CM; Yang, OO et al. (2008). „Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes”. Journal of immunology 181 (10): 7400–6. PMC 2682219. PMID 18981163. 
  4. Valenzuela, Hector F; Fuller, Thomas; Edwards, Jim; Finger, Danielle; Molgora, Brenda (2009). „Cycloastragenol extends T cell proliferation by increasing telomerase activity”. The Journal of Immunology 182 (Meeting Abstract Supplement). 
  5. Harley, Calvin B; Liu, Weimin; Blasco, Maria; Vera, Elsa; Andrews, William H; Briggs, Laura A; Raffaele, Joseph M (2011-01-02). „A Natural Product Telomerase Activator As Part of a Health Maintenance Program”. Rejuvenation Research 14 (1): 45–56. DOI:10.1089/rej.2010.1085.